

Evonik to expand probiotics portfolio in Asia with Ecobiol®

March 14, 2017

Essen. Evonik is to expand its portfolio in Asia with the probiotic Ecobiol®. It will be launched at VIV Asia in Bangkok. Ecobiol® is designed for the use in poultry production and aquaculture. The product was acquired by Evonik from the Spanish company NOREL S.A. in 2016.

Contact person
Dr. Jürgen Krauter
Head of Communications
Nutrition & Care
Phone +49 6181 59-6847
Fax +49 6181 59-76847
juergen.krauter@evonik.com

Ecobiol® helps to maintain the natural gut balance and has a positive effect on the gut microbiome that has been scientifically proven (in-vitro- and in in-vivo).

Contact person specialized press
Michael Giffels
Head of Communications
Animal Nutrition
Phone +49 6181 59-3763
michael.giffels@evonik.com

“Ecobiol® is new in our portfolio. We are convinced of the product’s high potential and its applicability in various fields by virtue of unique properties”, says Emmanuel Auer, Head of the Animal Nutrition business line at Evonik. “We consider Ecobiol® a key element towards the reduction of antibiotic growth promoters. This way, we contribute to healthy and sustainable animal nutrition.”

A healthy gut prevents from inflammatory diseases which can cause high costs in livestock management. In poultry production, enteric disorders caused by pathogenic bacteria such as *Clostridium perfringens*, lead to a financial loss of several billion US dollar annually.

“The product Ecobiol® shows very positive results in both poultry and aquaculture, for instance under various stress conditions. That has been demonstrated in scientific studies as well as in commercial use. For our customers in South East Asia this is of focal interest, particularly in shrimp farming”, says Peter Freisler, Head of Gut Health Solutions.

Evonik Nutrition & Care GmbH
Rellinghauser Straße 1-11
45128 Essen
Telefon +49 201 177-01
Fax +49 201 177-3475
Germany

www.evonik.com

Evonik intends to assume a leading role in the field of sustainable and antibiotic-free livestock management. In addition to the products Fecinor® and Ecobiol® from NOREL S.A., Evonik has recently enlarged its product line with GutCare® PY1, the first own developed probiotic. In January 2017, GutCare® PY1 was introduced in the U.S. market with other countries to follow.

Supervisory Board
Dr. Ralph Sven Kaufmann, Chairman

Management Board
Dr. Reiner Beste, Chairman
Dr. Hans Josef Ritzert
Michael Gattermann
Markus Schäfer

Registered office Essen
Registered court
Essen local court
Commercial registry B 25784
HR no. FN 431387 v

Evonik's Animal Nutrition business line has over sixty years of experience in the manufacture of essential amino acids and provides solutions for efficient and sustainable animal nutrition to customers in over one hundred countries. Evonik wants to make an even greater contribution to the efficiency and sustainability of animal feed by complementing its portfolio with innovative feed additives beyond amino acids in order to create additional value for its customers.

Evonik's products and services in the area of animal nutrition play a key role worldwide in the production of healthy and affordable food, while preserving natural resources and reducing the ecological footprint.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12,7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around €4.3 billion in 2016.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.